Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer.
about
Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancerImmunotherapy for lung cancer: advances and prospectsManagement of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancerEfficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer.Targeting the PD-1 pathway: a promising future for the treatment of melanoma.PD-1 gene promoter polymorphisms correlate with a poor prognosis in non-small cell lung cancerCancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment.Nomogram to Predict Occult N2 Lymph Nodes Metastases in Patients With Squamous Nonsmall Cell Lung Cancer.Combination of body mass index and oxidized low density lipoprotein receptor 1 in prognosis prediction of patients with squamous non-small cell lung cancer.Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer.Impact of gefitinib in early stage treatment on circulating cytokines and lymphocytes for patients with advanced non-small cell lung cancer.Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer.Unmet needs in squamous cell carcinoma of the lung: potential role for immunotherapy.Immunotherapy and lung cancer: current developments and novel targeted therapies.Best practice in the treatment of advanced squamous cell lung cancer.Nivolumab: a review in advanced squamous non-small cell lung cancer.Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration.Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer.Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.Immunological markers predict the prognosis of patients with squamous non-small cell lung cancer.Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status.The immunocheckpoints in modern oncology: the next 15 years.Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma.Human αβ and γδ T Cells in Skin Immunity and Disease.Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancerAdvances and Prospects in Cancer Immunotherapy
P2860
Q26745590-BBE6724B-FCEB-45C1-9EDC-DE7B562EF591Q26750617-0D7E669E-F619-4F0E-853A-2DFFBFE469EAQ26865779-BC055D26-63A0-48C8-8530-E27CA104A1B6Q33738921-A647F614-9E29-4E29-9EAE-48549AE1A9B2Q33946513-A35C6E48-74FE-4C18-BAAB-BC42F36A457EQ34265875-CD474D3E-4469-4127-BB2E-E4F6E0E0DD90Q35668604-A530D29C-F4CE-4C6C-8722-01A71DD86F1AQ36299306-DB6E038D-BD49-446F-854D-2D9AFE7C0813Q36355874-70BA501B-DB54-415A-9F2A-2259218A9B0CQ36916445-E8D7A90F-44EE-4DBC-BABB-D2165CC1D414Q37669516-EF2F1BF4-26E6-4243-AFE9-E011835989E1Q38115968-D27BEB40-5482-46E3-91E8-BC1205353909Q38205723-418BCBAE-C34B-4444-BABF-8A68A01A6BBFQ38286376-89892148-CB53-435A-BDB7-9AF496107CB1Q38435967-A0A65B0A-9F53-4460-A854-B10DC868B495Q38619640-958CB321-287C-43DE-91DA-A28369133565Q38688006-B0EF3112-2360-4671-86E7-B26DD69A6747Q38836875-125342BD-AE90-4825-A8FE-D2DF16E66F63Q38938285-B0B215F4-2EB6-47A5-A701-ADDE36B0245AQ39003812-A8D96555-7D8C-4859-BB5D-B91695EFCB76Q41578307-54D8CE09-D30E-4D9B-B75F-216F5C879CB9Q48461416-B516C239-21B4-4772-BFFA-E79D1F12D911Q51416101-7EBC0C70-C175-4AE8-BD72-EB4E20157FBEQ55265385-CA207246-45F2-46CF-8E8B-01E5B2A6B68DQ57494117-32352D96-003A-4D80-B310-75073CE0F86EQ59072375-DB9AB7E3-CDFC-4F13-9A92-185BE29A9C33
P2860
Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Rationale for targeting the im ...... of non-small-cell lung cancer.
@en
type
label
Rationale for targeting the im ...... of non-small-cell lung cancer.
@en
prefLabel
Rationale for targeting the im ...... of non-small-cell lung cancer.
@en
P2093
P2860
P921
P356
P1433
P1476
Rationale for targeting the im ...... of non-small-cell lung cancer
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDS647
P50
P5008
P577
2013-02-07T00:00:00Z